PHARMACOTHERAPY OF NON-SMALL CELL LUNG CANCER: A SHORT REVIEW

  • Balaji O Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.

Abstract

 Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28% deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC

Keywords: Tobacco, Programmed cell death pathway, Immune checkpoints, Platinum compounds.

References

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
2. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: Geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 2006;24:2137-50.
4. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001;31:123-37.
5. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138:281-93.
6. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
8. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007;58:95-103.
9. Tay K, Gutierrez M, Giaccone G. Platinum compounds in lung cancer: Current status. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. New York: Humana Press; 2009. p. 231-42.
10. Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest 2000;117:144S-151S.
11. Manegold C. Gemcitabine (Gemzar®) in non-small cell lung cancer. Expert Rev Anticancer Ther 2004;4:345-60.
12. Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs 2014;74:403-13.
13. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54.
14. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: Crizotinib and beyond. Clin Adv Hematol Oncol 2014;12:429-39.
15. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3:53.
Statistics
332 Views | 601 Downloads
How to Cite
O, B. “PHARMACOTHERAPY OF NON-SMALL CELL LUNG CANCER: A SHORT REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 3, Mar. 2018, pp. 7-10, doi:10.22159/ajpcr.2018.v11i3.23253.
Section
Review Article(s)